- Home
- JILL vs IMMP Comparison
JILL vs IMMP Comparison
Compare JILL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- IMMP
- Stock Information
- Founded
- JILL 1959
- IMMP 1987
- Country
- JILL United States
- IMMP Australia
- Employees
- JILL N/A
- IMMP N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- JILL Consumer Discretionary
- IMMP Health Care
- Exchange
- JILL Nasdaq
- IMMP Nasdaq
- Market Cap
- JILL 233.1M
- IMMP 251.8M
- IPO Year
- JILL 2017
- IMMP N/A
- Fundamental
- Price
- JILL $15.40
- IMMP $1.97
- Analyst Decision
- JILL Buy
- IMMP Buy
- Analyst Count
- JILL 4
- IMMP 1
- Target Price
- JILL $20.00
- IMMP $7.00
- AVG Volume (30 Days)
- JILL 53.2K
- IMMP 204.1K
- Earning Date
- JILL 12-10-2025
- IMMP 10-10-2025
- Dividend Yield
- JILL 2.08%
- IMMP N/A
- EPS Growth
- JILL N/A
- IMMP N/A
- EPS
- JILL 2.39
- IMMP N/A
- Revenue
- JILL $601,713,000.00
- IMMP $3,306,742.00
- Revenue This Year
- JILL $0.87
- IMMP $16.82
- Revenue Next Year
- JILL $2.44
- IMMP N/A
- P/E Ratio
- JILL $6.45
- IMMP N/A
- Revenue Growth
- JILL N/A
- IMMP 31.28
- 52 Week Low
- JILL $13.36
- IMMP $1.32
- 52 Week High
- JILL $30.40
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- JILL 42.32
- IMMP 52.16
- Support Level
- JILL $15.00
- IMMP $1.96
- Resistance Level
- JILL $16.85
- IMMP $2.17
- Average True Range (ATR)
- JILL 0.60
- IMMP 0.11
- MACD
- JILL 0.07
- IMMP -0.02
- Stochastic Oscillator
- JILL 33.49
- IMMP 13.89
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.